drugset / Trial / NCT04058535
Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, efficacy and pharmacokinetics of repeated intravitreal administration of ALT-L9 2 mg/50uL compared with Eylea in patients with neovascular Age-related macular degeneration.
Timeline
- Start
- 2020-02-05
- Primary completion
- 2020-12-22
- Completion
- 2020-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALT-L9 | Unknown | 2 mg | Intravitreal |
| Comparator | Aflibercept | Protein / enzyme biologic | 0.05 ml | Intravitreal |